Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma

TamPub

Näytä suppeat kuvailutiedot

dc.contributor.author Korja, Miikka -
dc.contributor.author Jokilammi, Aanne -
dc.contributor.author Salmi, Toivo T -
dc.contributor.author Kalimo, Hannu -
dc.contributor.author Pelliniemi, Tarja-Terttu -
dc.contributor.author Isola, Jorma -
dc.contributor.author Rantala, Immo -
dc.contributor.author Haapasalo, Hannu -
dc.contributor.author Finne, Jukka -
dc.date.accessioned 2012-06-17T20:16:41Z
dc.date.available 2012-06-15 06:30:34 -
dc.date.available 2012-06-17T20:16:41Z
dc.date.issued 2009 -
dc.identifier.issn 1471-2407 -
dc.identifier.uri http://tampub.uta.fi/handle/10024/66295
dc.description BioMed Central Open access -
dc.description.abstract Background The expression of a neural crest stem cell marker, polysialic acid (polySia), and its main carrier, neural cell adhesion molecule (NCAM), have been detected in some malignant tumors with high metastatic activity and unfavorable prognosis, but the diagnostic and prognostic value of polySia-NCAM in neuroblastoma is unclear. Methods A tumor tissue microarray (TMA) of 36 paraffin-embedded neuroblastoma samples was utilized to detect polySia-NCAM expression with a polySia-binding fluorescent fusion protein, and polySia-NCAM expression was compared with clinical stage, age, MYCN amplification status, histology (INPC), and proliferation index (PI). Results PolySia-NCAM-positive neuroblastoma patients had more often metastases at diagnosis, and polySia-NCAM expression associated with advanced disease (P = 0.047). Most interestingly, absence of polySia-NCAM-expressing tumor cells in TMA samples, however, was a strong unfavorable prognostic factor for overall survival in advanced disease (P = 0.0004), especially when MYCN was not amplified. PolySia-NCAM-expressing bone marrow metastases were easily detected in smears, aspirates and biopsies. Conclusion PolySia-NCAM appears to be a new clinically significant molecular marker in neuroblastoma, hopefully with additional value in neuroblastoma risk stratification. -
dc.language.iso en -
dc.title Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma -
dc.type fi=Artikkeli aikakauslehdessä | en=Journal article| -
dc.identifier.urn urn:nbn:uta-3-556 -
dc.identifier.doi 10.1186/1471-2407-9-57 -
dc.type.version fi=Kustantajan versio | en=Publisher's version| -
dc.subject.okm fi=Lääketieteen bioteknologia | en=Medical biotechnology| -
dc.journal.title BMC Cancer -
dc.journal.volume 9 -
dc.journal.number 57 -
dc.journal.volumepagerange 1-8 -
dc.oldstats 70 -

Viite kuuluu kokoelmiin:

Näytä suppeat kuvailutiedot